Payment overview · 2025
General Payments
$154.15
8 reported records · 7 companies
Healthcare provider profile · identity verified
Mukunda Singh, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CONCORD, NC · NPI 1487185534
Verified facts
What the public records show
CMS Open Payments records show Mukunda Singh, MD received $154.15 in general payments during 2025 across 8 reported records.
PFIZER INC. accounted for 25.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $38.88 | 25.2% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $22.82 | 14.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $21.67 | 14.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.05 | 13.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.60 | 12.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.05 | 11.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.08 | 9.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $154.15 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $38.88 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $38.88 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $22.82 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $21.67 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.05 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 170 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 108 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 81 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 74 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
108 | 26 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
170 | 32 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
74 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
108 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
81 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
170 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 513 | 147 |
| Amlodipine Besylate | Amlodipine Besylate | 358 | 96 |
| Omeprazole | Omeprazole | 248 | 60 |
| Lisinopril | Lisinopril | 225 | 61 |
| Gabapentin | Gabapentin | 208 | 56 |
| Losartan Potassium | Losartan Potassium | 206 | 58 |
| Eliquis | Apixaban | 170 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 168 | 46 |
| Metformin Hcl | Metformin Hcl | 150 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 145 | 39 |
| Levothyroxine Sodium | Levothyroxine Sodium | 142 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 113 | 28 |
| Jardiance | Empagliflozin | 108 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 107 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 97 | 26 |
| Furosemide | Furosemide | 95 | 35 |
| Hydralazine Hcl | Hydralazine Hcl | 94 | 23 |
| Carvedilol | Carvedilol | 89 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 88 | 33 |
| Metformin Hcl Er | Metformin Hcl | 83 | 26 |
| Tramadol Hcl | Tramadol Hcl | 83 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 81 | 21 |
| Mounjaro | Tirzepatide | 81 | 15 |
| Ozempic | Semaglutide | 80 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 74 | 15 |
| Trazodone Hcl | Trazodone Hcl | 72 | 19 |
| Ezetimibe | Ezetimibe | 71 | 23 |
| Potassium Chloride | Potassium Chloride | 71 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 68 | 21 |
| Famotidine | Famotidine | 65 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 62 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 62 | 23 |
| Chlorthalidone | Chlorthalidone | 60 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 16 |
| Allopurinol | Allopurinol | 55 | 12 |
| Spironolactone | Spironolactone | 53 | 18 |
| Prednisone | Prednisone | 51 | 40 |
| Mirtazapine | Mirtazapine | 49 | 12 |
| Alprazolam | Alprazolam | 45 | 15 |
| Sertraline Hcl | Sertraline Hcl | 45 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 44 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 44 | 20 |
| Meloxicam | Meloxicam | 43 | 11 |
| Montelukast Sodium | Montelukast Sodium | 42 | 11 |
| Trulicity | Dulaglutide | 42 | suppressed |
| Nifedipine Er | Nifedipine | 40 | 13 |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 35 |
| Buspirone Hcl | Buspirone Hcl | 37 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Atenolol | Atenolol | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 29 |
| Torsemide | Torsemide | 34 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 32 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Simvastatin | Simvastatin | 31 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | 12 |
| Pregabalin | Pregabalin | 24 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 19 |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 21 | 14 |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 18 |
| Nitroglycerin | Nitroglycerin | 18 | 11 |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Fluconazole | Fluconazole | 15 | 12 |
| Methylprednisolone | Methylprednisolone | 15 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Praluent Pen | Alirocumab | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $154.15 · 8 records | PFIZER INC. | AREXVY, ELIQUIS, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, Omnipod, TRELEGY ELLIPTA, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error